Close menu




January 26th, 2022 | 11:17 CET

Novavax, CoinSmart, Netflix - A buy after significant setbacks?

  • Investments
Photo credits: pixabay.com

The last few weeks have been tough for vaccine makers, cryptocurrencies and tech companies. In the case of vaccine manufacturers, concerns about a possible endemic disease caused by OmiCron was the reason for falling prices. In addition, there were the rumors about Pfizergate. Cryptocurrencies have been consolidating since early November. Allegedly, the US government is planning a crypto law, but contents are not yet known. For tech companies, the FED's expected interest rate hike, likely to be announced on January 26, brings uncertainty and makes investors rethink their investment strategy. Out of tech stocks, into value stocks. We look at one Company from each sector today.

time to read: 4 minutes | Author: Armin Schulz
ISIN: NOVAVAX INC. DL-_01 | US6700024010 , Coinsmart Financial Inc. | CA19260N1042 , NETFLIX INC. DL-_001 | US64110L1061

Table of contents:


    Novavax - Sometimes, the stock market is not rational

    The US biotech company Novavax is a bit of a paradox. The vaccine maker offers an alternative to mRNA and vector vaccines and thus could be interesting for vaccine skeptics. But while just a few months ago, every approval for a new country was greeted with jumps in the share price, the situation is now completely different. In January alone, the Company received approvals for South Africa, South Korea and Australia. The shares have not reacted to this news with any upward movement.

    From the Company's point of view, it is in a much better position than it was a year ago when there were not so many approvals and purchase agreements. However, the stock was at USD 331.68 and is now at about USD 77. What is clear is that Omicron is unsettling investors. Is this variant the end of the pandemic? Some countries are now foregoing protective measures, and Biden has failed in court with his mandatory vaccination. As an investor, it is important to remember that the Company has firm orders, sits on about USD 2 billion in cash and has a market cap of just USD 4.5 billion.

    The market no longer seems to be acting rationally at the moment. The euphoria of the past year has disappeared, and the stock has lost 50% since the beginning of the year. The question is where a bottom can be formed. The next support is not until USD 61.50, a breakout edge from 2020. Below that, the next support level follows at USD 40.50. However, the market value would be in cash, and there are, after all, other products in the pipeline. On January 24, a distinct hammer was formed, indicating a reversal, provided that the low is no longer undercut on a closing price basis.

    CoinSmart - Strong growth and a lot of future imagination

    CoinSmart is based in Canada and provides customers with a secure and intuitive trading platform for cryptocurrencies. The Company's philosophy is to put the customer first. To build trust, the Company has complied with the required regulations in each market to obtain the licenses and permits. In addition, customers are offered a 3-step training process because only successful customers are long-term customers. The Company is available 24/7 for its customers in case of any problems, by email, phone or chat. Soon, a chatbot with artificial intelligence will help handle the increasing support requests.

    The requests are increasing because customer numbers have grown rapidly since 2018. While there were 26,507 customers on December 31, 2020, there were 158,600 users on October 31, 2021. The Company is now active in 40 markets. Europe has also already been opened up via Estonia. Approvals for some US states and Australia are still pending.

    Last December, the Company achieved record sales of CAD 2.15 million. At the same time, it is already operating profitably and is debt-free. Compared to other crypto exchanges such as Netcoins or Voyager, the Company is clearly undervalued. Therefore, the management announced a share buyback program on January 18 for a maximum of 2,764,765 shares out of currently just over 60 million outstanding shares. For the future, CEO Justin Hartzman wants to offer more financial services based on blockchain. The topics involved include credit and debit cards, tokenization of tangible assets, NFTs, and more. Those who want to get a more detailed picture of the Company should register for the International Investment Forum. There, the CEO will present and answer questions live. At the current share price of CAD 0.72, the market capitalization is only CAD 46.5 million.

    Netflix - Weak growth prospects

    On January 20, Netflix presented its annual figures. Revenue increased by 19% to USD 30 billion, and earnings climbed by 35% to USD 6.2 billion. The Company has 222 million paying customers, of which 8.3 million were newly acquired in the fourth quarter of 2021. Although this reads positively at first glance, it was a reason to part with the stock for many investors - the reason being the weaker growth figures. The Group itself had expected 8.5 million new subscriptions. In addition, some analysts had hoped for more customer traffic after the release of the blockbuster series Squid Games.

    The valuations of tech companies are considered too high, especially given the expected interest rate increases. In mid-November, the share was still above UDS 700. Before the figures, the value was trading at USD 508.25. After the announcement, the share fell another 30% from its peak and marked a low at USD 351.46. The Company expects only 2.5 million new users in the coming quarter. Perhaps they intentionally stacked low to then surprise on the upside. The fact is that the Corona Bonus, which brought the Company many new customers, has probably been used up.

    In addition, the number of competitors is growing. In Germany, Peacock is a new streaming provider. Nevertheless, Netflix has a clear lead over the competition in terms of content volume. Not for nothing does the company point to the most Emmy winners of any broadcaster and the most Oscar-winning and nominated film studio in its letter to shareholders. Whether the stock has found a bottom yet remains to be seen. First, it has to get through the FED announcement on January 26.


    All three groups grew last year, but things are not always rational on the stock market. Novavax is doing much better than a year ago, but the stock is trading 80% lower. CoinSmart offers a regulated crypto trading platform and is growing tremendously fast. Unlike its competitors, the Company is already profitable and has a lot of plans. Netflix was badly punished for its outlook, but the streaming service is still the top dog in the industry.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Armin Schulz

    Born in Mönchengladbach, he studied business administration in the Netherlands. In the course of his studies he came into contact with the stock exchange for the first time. He has more than 25 years of experience in stock market business.

    About the author



    Related comments:

    Commented by Juliane Zielonka on September 30th, 2022 | 10:59 CEST

    Biogen, XPhyto, BioNTech: Alzheimer's disease, depression, cancer - Pharma for life

    • Biotechnology
    • Pharma
    • Investments
    • Technology

    About 350 million people worldwide are affected by depression, a disorder of the brain. Each person also has a 16 to 20% chance of becoming depressed. Reason enough for the Canadian Company XPhyto Therapeutics to research a drug that is not addictive and can defeat the mental health-related medical condition. This week, Biogen, among others, achieved a breakthrough with an active substance against Alzheimer's disease. And if you follow the Bundesliga closely, you may be aware of the cases of testicular cancer among the players. Now BioNTech senses a new opportunity...

    Read

    Commented by Fabian Lorenz on September 29th, 2022 | 13:17 CEST

    Up to 200% share price potential: Kion, BioNTech, Aspermont in analyst check

    • Technology
    • Biotechnology
    • Investments

    The profit warning was a shock for Kion shareholders. Accordingly, the share price halved to EUR 20 in September alone. Now analysts are also slashing their estimates. The price targets for the forklift manufacturer are falling accordingly. Berenberg surprises with a high price target for the BioNTech share. At the same time, the analysts emphasize their hope for a continued generous dividend. Shareholders could thus be kept in good spirits until the next blockbuster. The roadshow of Aspermont in Germany has probably also created a good mood. At least the share price has jumped. The current consolidation could be an entry opportunity. Analysts see a price potential of over 200%.

    Read

    Commented by Carsten Mainitz on September 29th, 2022 | 12:01 CEST

    Verbio, Kleos Space, KWS Saat - This news is moving share prices!

    • Space
    • Technology
    • Investments

    Increased uncertainties in geopolitics, rampant inflation with exploding commodity and energy prices, and higher interest rates are making it increasingly difficult for companies to meet the forecasts they issued at the beginning of the year. Recent examples include battery manufacturer Varta and real estate financier Hypoport, which had to withdraw their annual targets. In addition, however, a number of companies have been able to surprise on the upside despite all the challenges.

    Read